Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-08-22
2006-08-22
Wessendorf, T. D. (Department: 1639)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S004000, C435S091500, C435S091500, C530S388750, C530S350000
Reexamination Certificate
active
07094555
ABSTRACT:
The present invention provides of using multimeric MHC class II/peptide complexes. In one aspect, methods provided for identifying MHC class II-restricted immune epitopes of a predetermined polypeptide antigen. Methods for identifying an immunostimulatory epitope for a predetermined polypeptide antigen are provided. In a related aspect, methods for screening a therapeutic polypeptide agent for an MHC class II epitope are provided. In other aspects, methods for modulating T cells and for determining or monitoring an MHC class II-restricted immune status of a patient are also provided.
REFERENCES:
patent: 5635363 (1997-06-01), Altman et al.
patent: 5824315 (1998-10-01), Nag
patent: 6194207 (2001-02-01), Bell et al.
patent: 6194302 (2001-02-01), Shen
patent: 6211342 (2001-04-01), Hirsch et al.
patent: 0 239 400 (1987-09-01), None
patent: WO 97/35991 (1997-10-01), None
patent: WO98/06749 (1998-02-01), None
patent: WO 99/50637 (1999-10-01), None
Kunkel et al., “Contact-site cross-linking agents,”Mol. Cell. Biochem.34:3-13 (1981).
Marsh, “HLA class II region sequences, 1998,”Tissue Antigens51:467-507 (1998).
Altman et al., “Formation of functional peptide complexes of class II major histocompatibility complex protenis from subunits produced inEscherichia coli,” Proc.Natl. Acad. Sci. USA90:10330-34 (Nov. 1993).
Altman et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes,”Science274:94-96 (Oct. 4, 1996).
Arimilli et al., “Refolding and Reconstitution of Functionally Active Complexes of Human Leukoycte Antigen DR2 and Myelin Basic Protein Peptide from Recombinant α and β Polypeptide Chains,”J. Biol. Chem.270(2):971-977 (Jan. 13, 1995).
Atkinson et al., “Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes,”Lancet339:458-459 (Feb. 22, 1992).
Benjamin and Datta, “Modified Pulse Field Gel Electrophoresis Technique Using Pefabloc® SC for AnalyzingListeria monocytogenesDNA,”Biochemica2:30-31 (1995).
Blake et al., “The Importance of Exogenous Antigen in Priming the Human CD8+T Cell Response: Lessons from the EBV Nuclear Antigen EBNA1,”J. Immunol. 165: 7078-87 (2000).
Brosterhus et al., “Enrichment and detection of live antigen-specific CD4+and CD8+T cells based on cytokine secretion,”Eur. J. Immunol. 29:4053 (1999).
Brusic et al., “MHCPEP, a database of MHC-binding peptides: update 1997,”Nucleic Acids Res.26:368-371 (1998).
Brusic et al., “Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network,”Bioinformatics14:121-30 (1998).
Callan et al., “Direct Visualization of Antigen-pecific CD8+ T Cells during the Primary Immune Response to Epstein-Barr Virusin vivo,” J.Exp. Med.187:1395-1402 (1998).
Cameron et al., “Cutting Edge: Detection of Antigen-Specific CD4+T Cells by HLA-DR1 Oligomers is Dependent on the T Cell Activation State,”J. Immunol.166:741-745 (2001).
Chang et al., “A general method for facilitating heterodimeric pairing between two proteins: Application to expression of α and β T-cell receptor extracellular segments,”Proc. Natl. Acad. Sci. USA91:11408-11412 (1994).
Chang et al., “Identification of HLA-A3 and -B7-Restricted CTL Response to Hepatitis CVirus in Patients with Acute and Chronic Hepatitis C,”J. Immunol.162:1156-1164 (1999).
Cochlovius et al., “In Vitro and In Vivo Induction of a Th Cell Response Toward Peptides of the Melanoma-Associated Glycoprotein 100 Protein Selected by the TEPITOPE Program,”J. Immunol.165:4731-41 (2000).
Crawford et al., “Detection of Antigen-Specific T Cells with Multivalent Soluble Class II MHC Covalent Peptide Complexes,”Immunity8:675-682 (1998).
Cwynarski et al., “Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation,”Blood97:1232-40 (Mar. 1, 2001).
De Lalla et al., “Cutting Edge: Identification of Novel T Cell Epitopes inLol p5a by Computational Prediction,”J. Immunol.163:1725-29 (1999).
Demotz et al., “The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86,”Eur. J. Immunol.23:425-32 (1993).
Denkberg et al., “Recombinant human single-chain MHC-peptide complexes made fromE. colibyin vitrorefolding: functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens,”Eur. J. Immunol.30(12):3522-32 (Dec. 2000).
Dessen et al., “X-Ray Crystal Structure of HLA-DR4 (DRA*0101, DRB1*0401) Complexed with a Peptide from Human Collagen II,”Immunity7:473-481 (Oct. 1997).
Dunbar et al., “Cutting Edge: Rapid Cloning of Tumor-Specific CTL Suitable for Adoptive Immunotherapy of Melanoma,”J. Immunol.162:6959 (1999).
Endl et al., “Identification of Naturally Processed T Cell Epitopes from Glutamic Acid Decarboxylase Presented in the Context of HLA-DR Alleles by T Lymphocytes of Recent Onset IDDM Patients,”J. Clin. Invest.99:2405-15 (May 1997).
Ettinger and Kwok, “A Peptide Binding Motif for HLA-DQA*0102/DQB1*0602, the Class II MHC Molecule Associated with Dominant Protection in Insulin-Dependent Diabetes Mellitus,”J. Immunol.160:2365-73 (1998).
Ettinger et al., “Exceptional Stability of the HLA-DQA1*0102/DQB1*0602 αβ Protein Dimer, the Class II MHC Molecule Associated with Protection from Insulin-Dependent Diabetes Mellitus,”J. Immunol.161:6439-6445 (1998).
Ettinger et al., “β57-Asp Plays an Essential Role in the Unique SDS Stability of HLA-DQA1*0102/DQB1*0602 αβ Protein Dimer, the Class II MHC Allele Associated with Protection from Insulin-Dependent Diabetes Mellitus,”J. Immunol.165:3232-38 (2000).
Falk et al., “Induction and Suppression of an Autoimmune Disease by Oligomerized T Cell Epitopes: Enhanced In Vivo Potency of Encephalitogenic Peptides,”J. Exp. Med.191:717-730 (Feb. 21, 2000).
Fraser et al., “Signal transduction events leading to T-cell lymphokine gene expression,”Immunol. Today14:357-362 (1993).
Gallimore et al., “Induction and Exhaustion of Lymphocytic Choriomeningitis Virus-specific Cytotoxic T Lymphocytes Visualized Using Soluble Tetrameric Major Histocompatibility Complex Class I-Peptide Complexes,”J. Exp. Med.187:1383-1393 (May 4, 1998).
Garboczi et al., “HLA-A2-peptide complexes: Refolding and crystallization of molecules expressed inEscherichia coliand complexed with single antigenic peptides,”Proc. Natl. Acad. Sci. USA89:3429-33 (Apr. 1992).
Geluk et al., “Identification of Major Epitopes ofMycobacterium tuberculosisAG85B That Are Recognized by HLA-A*0201-Restricted CD8+T Cells in HLA-Transgenic Mice and Humans,”J. Immunol.165:6463-71 (2000).
Hammer et al., “Precise Prediction of Major Histocompatibility Complex Class II-Peptide Interaction Based on Peptide Side Chain Scanning,”J. Exp. Med.180:2353-58 (Dec. 1994).
Hammer et al., “HLA Class II Peptide Binding Specificity and Autoimmunity,”Adv. Immunol66:67-100 (1997).
Honeyman et al., “Neural network-based prediction of candidate T-cell epitopes,”Nat. Biotechnol.16:966-69 (Oct. 1998).
Horton et al., “Gene Splicing by Overlap Extension: Tailor-Made Genes Using the Polymerase Chain Reaction,”Biotechniques8:528-535 (1990).
Kaufman et al., “Spontaneous loss of T-cell tolerance to glumatic acid decarboxylase in murine insulin-dependent diabetes,”Nature366:69-72 (Nov. 4, 1993).
Kern et al., “T cell epitope mapping by flow cytometry,”Nat. Med.4:975-978 (Aug. 1998).
Kim et al., “Direct Detection and Magnetic Isolation ofChlamydia trachomatisMajor Outer Membrane Protein-Specific CD8+CTLs with HLA Class I Tetramers,”J. Immunol.165: 7285-92 (2000).
Klein et al., “H
Gebe John
Kwok William W.
Liu Andrew
Nepom Gerald
Reijonen Helena
Benaroya Research Institute at Virginia Mason
Townsend and Townsend / and Crew LLP
Wessendorf T. D.
LandOfFree
Methods of MHC class II epitope mapping, detection of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of MHC class II epitope mapping, detection of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of MHC class II epitope mapping, detection of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3653774